[Use of ursodeoxycholic acid in treatment of chronic hepatitis C].
HCV infection often results in chronic hepatitis (40-60% of patients). Interferon-alfa therapy induce complete remissions in around 25% of patients and temporary remissions in another 50% of cases. Because of low efficiency of this therapy, the combination therapy is still finding. The combination of interferon-alfa and ursodeoxycholic acid prolongs the efficacy of interferon-alfa in chronic hepatitis C by delaying the probability of biochemical relapse and/or by reducing its severity, without effecting HCV viremia.
Warunek
W
W
Katedra i Klinika Chorób Zakaznych Collegium Medicum UJ.
Zejc-Bajsarowicz
M
M
Librant-Suska
M
M
D002908:Chronic Disease; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D012074:Remission Induction; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D016898:Interferon-alpha; D014580:Ursodeoxycholic Acid